Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals has appointed Dr. Brinda Balakrishnan to its Board of Directors effective June 14, 2021. Dr. Balakrishnan currently serves as Group Vice President at BioMarin Pharmaceutical, where she oversees corporate strategy and business development. Her extensive background in biotech, particularly in rare diseases, is expected to enhance Aurinia's strategic direction and support its mission to treat autoimmune diseases like lupus nephritis. This move is seen as critical in positioning the company for future growth in the biopharmaceutical sector.

Aurinia Pharmaceuticals announced that all eight incumbent directors were re-elected during the annual general meeting held on June 7, 2021. The voting results showed a strong endorsement, with Peter Greenleaf receiving the highest approval at 92.18%. The Company also confirmed that all other matters voted on were approved. For detailed voting results, stakeholders can refer to the filings on SEDAR and EDGAR.

Aurinia Pharmaceuticals presented significant findings from its Phase 3 AURORA 1 study at the ERA-EDTA 2021 Congress. The analysis highlighted that voclosporin, when combined with MMF and low-dose steroids, achieved statistically significant renal response rates for lupus nephritis patients, even at stringent urine protein creatinine ratio (UPCR) targets. The study demonstrated that 40.8% of patients met the ≤0.5 mg/mg UPCR target versus 22.5% in the control group. LUPKYNIS, the first FDA-approved oral treatment for active lupus nephritis, showed a favorable safety profile with no unexpected adverse events.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its executive management will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:30 a.m. ET. Interested parties can access the live audio webcast via the 'News/Events' section on the Aurinia corporate website. A playback of the event will also be available after the live session. Aurinia focuses on therapies for serious diseases with high unmet needs and has developed LUPKYNIS™ (voclosporin), the first FDA-approved oral treatment for adult patients with active lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced an interim analysis of its AURORA 2 study, to be presented at the EULAR 2021 Congress from June 2-5, 2021. This analysis involved 216 subjects who transitioned from the Phase 3 AURORA study and demonstrated sustained reductions in proteinuria without affecting renal function over 104 weeks. The voclosporin treatment showed a greater reduction in urine protein creatinine ratio compared to controls. This data reinforces the clinical efficacy of LUPKYNIS, the first FDA-approved oral treatment for lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation in two upcoming investor conferences. The RBC Capital Markets Global Healthcare Conference is scheduled for May 19, 2021, at 10:55 a.m. ET, followed by the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021, at 10:45 a.m. ET. Interested parties can access the live audio webcast via the Investors section on Aurinia's website, with a replay available afterward. Aurinia focuses on delivering therapies for serious diseases, including LUPKYNIS™, the first FDA-approved oral treatment for active lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced its commitment to improving healthcare access for individuals affected by systemic lupus erythematosus (SLE) and lupus nephritis (LN), coinciding with World Lupus Day. The company is sponsoring grants to establish patient navigator programs aimed at underserved communities, particularly Black, Asian, and Hispanic populations disproportionately affected by LN. As the COVID-19 pandemic has hindered healthcare access, these programs are crucial for connecting patients to necessary resources and education. Organizations can apply for grants until June 1, 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the publication of Phase 3 AURORA 1 study results for LUPKYNIS (voclosporin) in treating lupus nephritis (LN). The study, published in The Lancet, demonstrated that LUPKYNIS combined with mycophenolate mofetil (MMF) and low-dose corticosteroids achieved a complete renal response rate of 41% at 52 weeks, significantly outpacing the 23% in the control group. Additionally, LUPKYNIS was well-tolerated, showing a comparable safety profile to the standard treatment. FDA approved LUPKYNIS in January 2021.

Aurinia Pharmaceuticals reported its financial results for Q1 2021, with revenues of $0.9 million attributed to the launch of LUPKYNIS, the first FDA-approved oral treatment for active lupus nephritis. The company experienced a net loss of $50.4 million or $0.40 per share, up from a $25.9 million loss in Q1 2020. Operating cash decreased to $360.9 million due to commercial infrastructure investments. Aurinia anticipates improved market access as healthcare facilities reopen. Upcoming milestones include EMA filing and new clinical trials.